The cell line development process involved several rounds of cloning and screening to identify a cell line with the desired characteristics, including:
68% from harvest to bulk drug substance. A Mab A Case Study In Bioprocess Development
Bioprocess development is the unsung hero of biotech. It turns scientific discovery into a tangible product, ensuring that the medicine is not only effective but safe, stable, and available for the patients who need it most. The cell line development process involved several rounds
The is a seminal 2009 document developed by the CMC-Biotech Working Group —a consortium including Amgen, Genentech, and Pfizer—to demonstrate how Quality by Design (QbD) principles can be applied to monoclonal antibody (mAb) bioprocessing . It serves as a practical roadmap for implementing International Council for Harmonisation (ICH) guidelines Q8(R2) , Q9 , and Q10 in a biotechnology environment. Core Framework of the A-Mab Study The is a seminal 2009 document developed by
The purified Mab-X is now in a low-pH, high-salt buffer unsuitable for injection. The case study addresses two final challenges:
This "flow-through" polishing step ensured that mAb-X achieved a purity level of .